Monitor for official NYSE delisting notice and subsequent plan submission. The missed filing extension suggests deeper accounting issues beyond simple delay, increasing risk of material weakness disclosure when filed. Consider this a red flag for governance and financial reporting reliability.
Price Chart
Executive Summary
Apimeds Pharmaceuticals failed to file its 2025 Form 10-K on time and expects to miss the 15-day extension, triggering a likely delisting notice from NYSE American. The delay is due to ongoing financial statement preparation and audit procedures.
Key Facts
- Filed Form 12b-25 on March 31, 2026, disclosing inability to file 2025 Form 10-K on time
- Now expects to miss the 15-day extension period under Rule 12b-25
- Delay attributed to ongoing financial statement finalization and audit procedures
- Expects to receive delisting notice from NYSE American for failure to meet continued listing requirements
- Currently targeting April 30, 2026, for 10-K filing but provides no assurance
Financial Impact
High risk of delisting; potential material weakness in financial controls; significant regulatory and reputational risk
Risk Factors
- Delisting from NYSE American if compliance plan is not accepted or timely executed
- Potential SEC enforcement action for continued reporting failures
- Reputational damage affecting investor confidence and partnership opportunities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-044657 |
| Document: 0001213900-26-044657-index-headers.html | 0001213900-26-044657 |
| Document: 0001213900-26-044657-index.html | 0001213900-26-044657 |
| Document: 0001213900-26-044657.txt | 0001213900-26-044657 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | — | $3.05 (−33.98%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | — | $3.05 (−25.61%) |
Sep 22, 2026 4w ago | 8-K | $2.29 | awaiting T+60 | — | $3.05 (+33.19%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $3.05 (−35.79%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $3.05 (−27.90%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $3.05 (−89.83%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $3.05 (−62.23%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $3.05 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers